Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 KBI Biopharma BVBA Launches Belgium Lab Operations | Contract Pharma

What are you searching for?

Sign in
Breaking News

KBI Biopharma BVBA Launches Belgium Lab Operations

Labs are co-located with JSR Life Sciences’ Amsphere A3 European mfg. site & represent KBI’s first Europe service offerings

By: Betsy Louda

, Contract Pharma

KBI Biopharma announced that its subsidiary KBI Biopharma BVBA has begun operations at its newly completed laboratories in Leuven, Belgium. 

The laboratories are co-located with JSR Life Sciences’ Amsphere A3 European manufacturing site and represent KBI’s first service offering based in Europe. KBI Biopharma BVBA initiated its first client-sponsored programs in May 2018.

KBI Biopharma BVBA has capabilities for GMP and non-GMP services including analytical development, formulation development, biopharmaceutical characterization and cGMP quality control testing for release and stability of drug substance and drug product.

“A key strength of this new facility is the utilization of our existing procedures and knowledge base,” said Cale Halbleib, PhD, director of Biopharmaceutical Development at KBI Biopharma BVBA. “Our Leuven site is a European extension of KBI’s well-established development and GMP testing expertise. We can now leverage those capabilities in both the US and EU including transfer and co-validation of analytical methods for customers.”

“The establishment of our analytical services laboratory in Belgium is a key strategic objective for KBI,” said president and chief executive officer of KBI Biopharma, Inc., Tim Kelly, PhD. “Through this expansion, we are building on our exceptional foundation in analytical sciences to offer an even more comprehensive solution to our client partners who seek to conduct clinical trials and register their products in the EU and US.”

To date, KBI has helped to advance more than 300 molecules in more than 70 unique health indications. By expanding its footprint into Europe, KBI will continue to accelerate an even broader range of drug development programs for its global client base.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics